Genetic Technologies Ltd (GENE) Stock Price & Overview
NASDAQ:GENE • US37185R4065
Current stock price
The current stock price of GENE is 0.765 USD. Today GENE is down by -1.92%. In the past month the price decreased by -3.89%. In the past year, price decreased by -79.19%.
GENE Key Statistics
- Market Cap
- 2.577M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.74
- Dividend Yield
- N/A
GENE Stock Performance
GENE Stock Chart
GENE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GENE. When comparing the yearly performance of all stocks, GENE is a bad performer in the overall market: 93.77% of all stocks are doing better.
GENE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GENE. GENE has a bad profitability rating. Also its financial health evaluation is rather negative.
GENE Earnings
GENE Forecast & Estimates
GENE Groups
Sector & Classification
GENE Financial Highlights
Over the last trailing twelve months GENE reported a non-GAAP Earnings per Share(EPS) of -2.74. The EPS increased by 19.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -194.25% | ||
| ROE | -656.53% | ||
| Debt/Equity | 0.36 |
GENE Ownership
GENE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 19.25 | 176.226B | ||
| DHR | DANAHER CORP | 22.42 | 133.897B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 124.29 | 40.886B | ||
| A | AGILENT TECHNOLOGIES INC | 16.71 | 31.453B | ||
| WAT | WATERS CORP | 20.66 | 29.331B | ||
| IQV | IQVIA HOLDINGS INC | 12.98 | 27.878B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 26.25 | 24.487B | ||
| ILMN | ILLUMINA INC | 23.6 | 19.01B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 29.9 | 17.085B | ||
| MEDP | MEDPACE HOLDINGS INC | 26.19 | 12.842B | ||
| RVTY | REVVITY INC | 15.8 | 9.608B | ||
| TEM | TEMPUS AI INC-CL A | N/A | 8.395B | ||
| TECH | BIO-TECHNE CORP | 23.32 | 8.054B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GENE
Company Profile
Genetic Technologies Ltd. operates as a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. The company is headquartered in Melbourne, Victoria and currently employs 60 full-time employees. The firm is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The firm offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The firm has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The firm operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor
Company Info
IPO: 1987-07-30
Genetic Technologies Ltd
60-66 Hanover St, Fitzroy
Melbourne VICTORIA 3065 AU
CEO: Simon Morriss
Employees: 55
Phone: 61394151135
Genetic Technologies Ltd / GENE FAQ
What does Genetic Technologies Ltd do?
Genetic Technologies Ltd. operates as a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. The company is headquartered in Melbourne, Victoria and currently employs 60 full-time employees. The firm is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The firm offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The firm has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The firm operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor
What is the current price of GENE stock?
The current stock price of GENE is 0.765 USD. The price decreased by -1.92% in the last trading session.
Does GENE stock pay dividends?
GENE does not pay a dividend.
How is the ChartMill rating for Genetic Technologies Ltd?
GENE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for GENE stock?
Genetic Technologies Ltd (GENE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.74).
What is the employee count for GENE stock?
Genetic Technologies Ltd (GENE) currently has 55 employees.